Skip to main content

Advertisement

SpringerLink
Log in

Body composition analysis in patients with myotonic dystrophy types 1 and 2

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Introduction

To date, there are only several reports on body composition in myotonic dystrophy type 1 (DM1) and there are no data for myotonic dystrophy type 2 (DM2). The aim was to analyze body composition of patients with DM1 and DM2, and its association with socio-demographic and clinical features of the diseases.

Methods

There were no statistical differences in sociodemographic features between 20 DM1 patients and 12 DM2 patients. Body composition was assessed by DEXA (dual-energy x-ray absorptiometry). A three-compartment model was used: bone mineral content (BMC), fat mass (FM), and lean tissue mass (LTM).

Results

Patients with DM1 and DM2 had similar total body mass (TBM), BMC, FM, and LTM. Patients with DM1 had higher trunk-limb fat index (TLFI) in comparison to DM2 patients which indicates visceral fat deposition in DM1 (1.16 ± 0.32 for DM1 vs. 0.87 ± 0.23 for DM2, p < 0.05). Right ribs bone mineral density was lower in DM2 group (0.68 ± 0.07 g/cm2 vs. 0.61 ± 0.09 g/cm2, p < 0.05). Higher percentage of FM in legs showed correlation with lower strength of the upper leg muscles in DM1 (ρ = − 0.47, p < 0.05). Higher muscle strength in DM2 patients was in correlation with higher bone mineral density (ρ = + 0.62, p < 0.05 for upper arm muscles, ρ = + 0.87, p < 0.01 for lower arm muscles, ρ = + 0.72, p < 0.05 for lower leg muscles).

Conclusion

DM1 patients had visceral obesity, and percentage of FM correlated with a degree of muscle weakness in upper legs. In DM2 patients, degree of muscle weakness was in correlation with higher FM index and lower bone mineral density.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schara U, Schoser BG (2006) Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 13:71–79

    Article  PubMed  Google Scholar 

  2. Wenninger S, Montagnese F, Schoser B (2018) Core clinical phenotypes in myotonic dystrophies. Front Neurol 9:303

    Article  PubMed  PubMed Central  Google Scholar 

  3. Harper PS, Monckton DG (2005) Myotonic dystrophy. In: Engel AG, Franzini-Amstrong C (eds) Myology: basic and clinical, 3rd edn. McGraw-Hill, New York, pp 1039–1076

    Google Scholar 

  4. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293(5531):864–867

    Article  CAS  PubMed  Google Scholar 

  5. Schoser B, Meola G (2018) Editorial: beyond borders: myotonic dystrophies-a European perception. Front Neurol 9:787

    Article  PubMed  PubMed Central  Google Scholar 

  6. Turner C, Hilton-Jones D (2010) The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry 81(4):358–367

    Article  PubMed  Google Scholar 

  7. Aitkens SL, Kilmer DD, Wright NC, McCrory MA (2005) Metabolic syndrome in neuromuscular disease. Arch Phys Med Rehabil 86(5):1030–1036

    Article  PubMed  Google Scholar 

  8. Rakocevic-Stojanovic V, Peric S, Lavrnic D, Popovic S, Ille T, Stevic Z, Basta I, Apostolski S (2010) Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurol Scand 121(2):94–98

    Article  CAS  PubMed  Google Scholar 

  9. Pruna L, Chatelin J, Pascal-Vigneron V, Kaminsky P (2011) Regional body composition and functional impairment in patients with myotonic dystrophy. Muscle Nerve 44(4):503–508

    Article  PubMed  Google Scholar 

  10. Cruz Guzmán Odel R, Chávez García AL, Rodríguez-Cruz M (2012) Muscular dystrophies at different ages: metabolic and endocrine alterations. Int J Endocrinol 2012:485376

    PubMed  Google Scholar 

  11. Perseghin G, Comola M, Scifo P, Benedini S, De Cobelli F, Lanzi R, Costantino F, Lattuada G, Battezzati A, Del Maschio A, Luzi L (2004) Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1. Am J Clin Nutr 80(2):357–364

    Article  CAS  PubMed  Google Scholar 

  12. Tieleman AA, Jenks KM, Kalkman JS, Borm G, van Engelen BG (2011) High disease impact of myotonic dystrophy type 2 on physical and mental functioning. J Neurol 258(10):1820–1826

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Savić Pavićević D, Miladinović J, Brkušanin M, Šviković S, Djurica S, Brajušković G, Romac S (2013) Molecular genetics and genetic testing in myotonic dystrophy type 1. Biomed Res Int 2013:391821

    Article  Google Scholar 

  14. Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P (2001) Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56(3):336–340

    Article  CAS  PubMed  Google Scholar 

  15. Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 14(11):1103–1109

    Article  CAS  PubMed  Google Scholar 

  16. Peric S, Maksimovic R, Banko B, Durdic M, Bjelica B, Bozovic I, Balcik Y, Pesovic J, Savic-Pavicevic D, Rakocevic-Stojanovic V (2017) Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies. J Neurol 264(9):1899–1908

    Article  CAS  PubMed  Google Scholar 

  17. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, Pourmand R, Otten RF, Bhakta D, Nair GV, Marashdeh MM, Zipes DP, Pascuzzi RM (2008) Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 358(25):2688–2697

    Article  CAS  PubMed  Google Scholar 

  18. Sedehizadeh S, David Brook J, Maddison P (2017) Body composition and clinical outcome measures in patients with myotonic dystrophy type 1. Neuromuscul Disord 27(3):286–289

    Article  PubMed  Google Scholar 

  19. Renna LV, Bosè F, Iachettini S, Fossati B, Saraceno L, Milani V, Colombo R, Meola G, Cardani R (2017) Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle. PLoS One 12(9):e0184987

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Passeri E, Bugiardini E, Sansone V, Pizzocaro A, Fulceri C, Valaperta R, Borgato S, Costa E, Bandera F, Ambrosi B, Meola G, Persani L, Corbetta S (2015) Gonadal failure is associated with visceral adiposity in myotonic dystrophies. Eur J Clin Invest 45(7):702–710

    Article  CAS  PubMed  Google Scholar 

  21. Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, Mcdermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd (2016) The myotonic dystrophy health index: correlations with clinical tests and patient function. Muscle Nerve 53(2):183–190

    Article  PubMed  Google Scholar 

  22. Dozio E, Passeri E, Cardani R, Benedini S, Aresta C, Valaperta R, Corsi Romanelli M, Meola G, Sansone V, Corbetta S (2017) Circulating irisin is reduced in male patients with type 1 and type 2 myotonic dystrophies. Front Endocrinol (Lausanne) 14(8):320

    Article  Google Scholar 

  23. Seijger CG, Drost G, Posma JM, van Engelen BG, Heijdra YF (2016) Overweight is an independent risk factor for reduced lung volumes in myotonic dystrophy type 1. PLoS One 11(3):e0152344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Danckworth F, Karabul N, Posa A, Hanisch F (2014) Risk factors for osteoporosis, falls and fractures in hereditary myopathies and sporadic inclusion body myositis - a cross sectional survey. Mol Genet Metab Rep 1:85–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Passeri E, Bugiardini E, Sansone VA, Valaperta R, Costa E, Ambrosi B, Meola G, Corbetta S (2013) Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies. J Neurol Sci 331(1–2):132–135

    Article  CAS  PubMed  Google Scholar 

  26. Terracciano C, Rastelli E, Morello M, Celi M, Bucci E, Antonini G, Porzio O, Tarantino U, Zenobi R, Massa R (2013) Vitamin D deficiency in myotonic dystrophy type 1. J Neurol 260(9):2330–2334

    Article  CAS  PubMed  Google Scholar 

  27. Dogan C, De Antonio M, Hamroun D, Varet H, Fabbro M, Rougier F, Amarof K, Arne Bes MC, Bedat-Millet AL, Behin A, Bellance R, Bouhour F, Boutte C, Boyer F, Campana-Salort E, Chapon F, Cintas P, Desnuelle C, Deschamps R, Drouin-Garraud V, Ferrer X, Gervais-Bernard H, Ghorab K, Laforet P, Magot A, Magy L, Menard D, Minot MC, Nadaj-Pakleza A, Pellieux S, Pereon Y, Preudhomme M, Pouget J, Sacconi S, Sole G, Stojkovich T, Tiffreau V, Urtizberea A, Vial C, Zagnoli F, Caranhac G, Bourlier C, Riviere G, Geille A, Gherardi RK, Eymard B, Puymirat J, Katsahian S, Bassez G (2016) Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study. PLoS One 11(2):e0148264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bozovic I, Peric S, Pesovic J, Bjelica B, Brkusanin M, Basta I, Bozic M, Sencanic I, Marjanovic A, Brankovic M, Savic-Pavicevic D, Rakocevic-Stojanovic V (2018) Myotonic dystrophy type 2 - data from the Serbian registry. J Neuromuscul Dis 5(4):461–469

    Article  PubMed  Google Scholar 

  29. Rakocevic-Stojanovic V, Peric S, Basta I, Dobricic V, Ralic V, Kacar A, Peric M, Novakovic I (2015) Variability of multisystemic features in myotonic dystrophy type 1-lessons from Serbian registry. Neurol Res 37(11):939–944

    Article  PubMed  Google Scholar 

Download references

Funding

The study was funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia under Grant [Number 175083].

Author information

Authors and Affiliations

  1. Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, 6, Dr. Subotic Street, Belgrade, 11000, Serbia

    Stojan Peric, Ivo Bozovic, Marija Banovic, Tamara Svabic, Marija Brankovic, Ivana Basta, Milena Jankovic & Vidosava Rakocevic-Stojanovic

  2. Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Dr Subotica starijeg 13, Belgrade, Serbia

    Tanja Nisic

  3. Neurology Clinic, Clinical Center Banja Luka, 12 beba street, Banja Luka, Bosnia and Herzegovina

    Milorad Vujnic

  4. Center for Human Genetics, University of Belgrade – Faculty of Biology, Studentski trg 16, Belgrade, Serbia

    Jovan Pesovic & Dusanka Savic-Pavicevic

Authors
  1. Stojan Peric
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivo Bozovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanja Nisic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marija Banovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Milorad Vujnic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tamara Svabic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jovan Pesovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marija Brankovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ivana Basta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Milena Jankovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dusanka Savic-Pavicevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Vidosava Rakocevic-Stojanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vidosava Rakocevic-Stojanovic.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peric, S., Bozovic, I., Nisic, T. et al. Body composition analysis in patients with myotonic dystrophy types 1 and 2. Neurol Sci 40, 1035–1040 (2019). https://doi.org/10.1007/s10072-019-03763-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-019-03763-0

Keywords

Search

Navigation